Table 2 Patient characteristics in the aHyC group (all patients who received aHyC) and in the documented control group

Number of patients

19

21

Age (years) at CRPC diagnosis, median (IQR)

74 (69–81)

72 (69–75)

Follow-up (months), median (IQR)

65 (35–81)

50 (41–59)

Deaths, n (%)

11 (58)

19 (90)

PSA at CRPC diagnosis, ng/mL

 Median (IQR)

7 (4–14)

11 (6–14)

 Mean ± SEM

14 ± 6

13 ± 3

Gleason score, n (%)

 8–10

16 (84)

12 (57)

 6–7

3 (16)

9 (43)

 Median (IQR)

9 (9–9)

8 (7–9)

Metastases at CRPC*, n (%)

 No metastases

12 (63)

15 (71)

 Oligometastases (≤ 3)

3 (21)

6 (29)

 Polymetastases (≥ 4)

4 (16)

0

Site of metastases*, n (%)

 Bone

4 (21)

4 (19)

 Lymph node

0

2 (10)

 Bone + lymph node

3 (16)

0

 Visceral

0

0

Next-in-line treatment (docetaxel, enzalutamide, abiraterone acetate) up to 30 September 2021

 Yes, n (%)

13 (68)

21 (100)

 TTNT (months), median (HR; 95% CI)

28 (0.31; 0.15–0.63)

16 (3.25; 1.59–6.64)